Therapix expects to have results of Tourette's drug trial by end of first quarter

TEL AVIV (Reuters) - Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.